As a trusted discovery partner, Eurofins Discovery transforms complex GPCR pharmacology intoclear, actionable insights through unmatched assay breadth, scientific expertise, and end-to-endcapabilities spanning target validation to candidate advancement. Backed by more than 30 years of GPCR experience, including 20+ years of successful Integrated Drug Discovery (IDD) expertise, and a portfolio of over 2,750 assays, covering one of the broadest ranges of GPCR targets in the industry, we provide the flexibility and expertise needed at every stage of discovery.
Beyond screening, our capabilities include custom assay development, deorphanization, biophysical characterization, translational models, and advanced pharmacology support. Combined with high-throughput execution and rapid turnaround times, we help generate the biologically relevant insights needed to reduce risk and advance the right candidates forward.
GPCR Screening Services
Flexible Study Formats
-
Screening campaigns
-
Mechanistic pharmacology studies
-
Custom assay solutions
-
Translational & advanced cell models
-
Cell-based and biochemical assays
-
In vitro efficacy studies
Functional Pharmacology & Binding Expertise
-
cAMP, β-Arrestin, calcium flux, receptor internalization
-
Radioligand binding, affinity determination, kinetic characterization
-
Biased signaling and allosteric modulation
-
Ortholog and species variant profiling
Integrated Discovery Capabilities
​​​​
-
Deorphanization & translational pharmacology
-
Assay development & high-throughput screening
-
Hit identification & lead optimization
-
Integrated drug discovery support
Pharmacology endpoints
​
Detailed characterization of GPCR activity and function
​
Capabilities span the key endpoints that describe how a receptor behaves
Key areas
​
Services across the discovery continuum
Advanced Pharmacology & Translational Models
Therapeutic focus
​
Where the science is applied
Deep coverage across the areas driving GPCR discovery today.
In the spotlight
​
Featured this year
​
A closer look at highlighted panels and newly launched capabilities
Signature panels
​
Peptide Hormone Class B Panel
​
Functional coverage of Class B GPCRs, the peptide hormone receptors central to metabolic and endocrine drug discovery
Recently ​launched
​
GSIS
​​
A newly launched addition to the metabolic portfolio, expanding options for physiologically relevant screening.
30+
years in GPCR experince
2,750+
validated functional and binding GPCR assays
300+
GPCR targets covered
GPCRome
broad coverage across the human GPCRome
One integrated platform
​​
The full power of Eurofins Discovery
​
These services are one part of an integrated GPCR platform. Combined with Eurofins DiscoverX products and Calixar membrane proteins, they span the entire discovery and development continuum.
Products
​
Eurofins DiscoverX
​
Validated GPCR cell lines, assay kits, and custom products, on the same platform as our services
​
View the DiscoverX page
Additional services
​​
Eurofins Discovery
​​​​
Key resources
​
Downloadable guides & references
​
Scientists-first materials to explore the science in depth.
Get in touch
​
Talk to the Eurofins Discovery team
​
Reach the group nearest you, or start a conversation through the Dr. GPCR ecosystem
Follow along on LinkedIn - or send us a note through your partner page